| PROFIBRIX BV Patent applications |
| Patent application number | Title | Published |
|---|
| 20120070477 | DRY POWDER FIBRIN SEALANT - A fibrin sealant comprises a mixture of first microparticles that comprise fibrinogen, second microparticles that comprise thrombin, and additive material. The additive material may be particulate, and may be, for instance, a biocompatible, water-absorbent, material, a biocompatible, water-swellable material, a biocompatible, water-insoluble material, a polysaccharide or silica. | 03-22-2012 |
| 20120064165 | TREATMENT OF TISSUE ADHESION - Dry powder compositions are useful in the treatment or prevention of tissue adhesions during or after surgery or during wound therapy. The dry powder compositions may contain trehalose. The dry powder compositions may be fibrin sealant compositions comprising fibrinogen and/or thrombin. | 03-15-2012 |
| 20120016465 | Biodegradable Extravascular Stent - The present invention relates to extravascular supports. In particular, to extravascular supports which are used in vein grafting. More in particular, it relates to extravascular supports which are biodegradable. | 01-19-2012 |
| 20110251580 | POWDER DELIVERY DEVICE - A device for the topical dispensing of a powder, typically a powder medicament, comprises, or is adapted to be coupled to, a powder receptacle and a gasflow generator. The gasflow generator is adapted, in use, to cause gas to flow through the device, which further comprises an agitator by which the powder and/or the powder receptacle can be mechanically agitated. Actuation of the gasflow generator, which causes gas to flow through the device and to entrain powder from the powder receptacle, thereby to dispense powder from the device, is accompanied by actuation of the agitator, causing the powder receptacle to be mechanically agitated, thereby facilitating the release of powder from the powder receptacle. | 10-13-2011 |
| 20110177524 | Recombinant Fibrinogen - The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system. | 07-21-2011 |
